ArticleInfection and immunity2008
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses.
Article in Infection and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 92 citations in OpenAlex.
- Architecture and regulatory functions of c-di-GMP signaling in classical Bordetella species.FEMS microbiology reviews · 2026Review
- The Bordetella type III secretion system effector BteA targets host eosinophil-epithelial signaling to promote IL-1Ra expression and persistence.Communications biology · 2025Article
- Limited response of primary nasal epithelial cells toMicrobiology spectrum · 2025Article
- Article
- Eosinophils as drivers of bacterial immunomodulation and persistence.Infection and immunity · 2024Review
- Gut bacterial type III secretion systems aggravate colitis in mice and serve as biomarkers of Crohn's disease.EBioMedicine · 2024Article
- T3SS chaperone of the CesT family is required for secretion of the anti-sigma factor BtrA inEmerging microbes & infections · 2023Article
- Cyclic di-GMP Regulates the Type III Secretion System and Virulence in Bordetella bronchiseptica.Infection and immunity · 2022Article
- Pathogenicity and virulence ofVirulence · 2021Review
- Pertussis in Individuals with Co-morbidities: A Systematic Review.Infectious diseases and therapy · 2021Review
- Article
- Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules · 2021Review
- Omics Analysis of Blood-Responsive Regulon inInternational journal of molecular sciences · 2021Article
- Comparative Omics Analysis of Historic and Recent Isolates of Bordetella pertussis and Effects of Genome Rearrangements on Evolution.Emerging infectious diseases · 2021Article
- Transcriptional Downregulation of a Type III Secretion System under Reducing Conditions in Bordetella pertussis.Journal of bacteriology · 2020Article
- Tracheal colonization factor A (TcfA) is a biomarker for rapid and specific detection of Bordetella pertussis.Scientific reports · 2020Article
- Cytotoxicity of the effector protein BteA was attenuated in Bordetella pertussis by insertion of an alanine residue.PLoS pathogens · 2020Article
- Adenylate Cyclase Toxin Tinkering With Monocyte-Macrophage Differentiation.Frontiers in immunology · 2020Review
- Review
- Enhancement of immune response against Bordetella spp. by disrupting immunomodulation.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Certain bacteria use a type III secretion system (TTSS) to deliver effector proteins that interfere with cell function into host cells. While transcription of genes encoding TTSS components has been demonstrated, studies to date have failed to identify TTSS effector proteins in Bordetella pertussis. Here we present the first evidence of a functionally active TTSS in B. pertussis. Three known TTSS effectors, Bsp22, BopN, and BopD, were identified as TTSS substrates in B. pertussis 12743. We found expression of Bsp22 in a significant proportion of clinical isolates but not in common laboratory-adapted strains of B. pertussis. We generated a TTSS mutant of B. pertussis 12743 and showed that it induced significantly lower respiratory tract colonization in mice than the wild-type bacteria. Respiratory infection of mice with the mutant bacteria induced significantly greater innate proinflammatory cytokine production in the lungs soon after challenge, and this correlated with significantly higher antigen-specific interleukin-17, gamma interferon, and immunoglobulin G responses later in infection. Our findings suggest that the TTSS subverts innate and adaptive immune responses during infection of the lungs and may be a functionally important virulence factor for B. pertussis infection of humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.